GHRH receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-24. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
== AFL career == Carlisle made his debut in Round 20 of the 2010 AFL season, against Collingwood, a game which the young team lost by 98 points. Essendon coach Matthew Knights claimed that Carlisle and fellow debutant, Stewart Crameri, will have "come away from the match with enormous knowledge of how hard they have to train now and how hard they have to work in the off-season to keep building their football." He had a break-out 2012, his consistency in the back-line did not go unnoticed, earning an AFL Rising Star nomination against Greater Western Sydney in Round 9. While Jake spent the majority of his time on the last line of defence, he also enjoyed the odd cameo role up forward. Fearless around packs and a strong contested mark, his impressive season was cut short with a foot injury in Round 19. Carlisle was a major factor of the Bombers' racing out to a 6–0 start and being 13–3 after Round 17 in 2013, his switches to the forward line providing an X-Factor in getting the bombers over the line, such as in Round 14 against the West Coast Eagles, where Carlisle kicked two late goals, including one to level the scores with under two minutes remaining, as the bombers earned a 7-point victory. In September 2015 Carlisle requested a trade out of Essendon after delaying contract talks until the end of the season.
=== Onset and duration === The psychoactive effects of LSD last on average between 7 and 11 hours, with a possible range of 4 to 22 hours. Higher doses tend to lead to a longer duration of action. The onset of action when administered orally is 0.4 to 1.0 hours on average, with a possible range of 0.1 to 1.8 hours. The time to peak effects given orally is 2.2 to 2.8 hours on average, with a range of 1.3 to 6.5 hours. The duration of LSD can be shortened through the use of trip killers or shorteners like ketanserin. In a clinical trial, ketanserin given 1 hour after LSD shortened its duration from 8.5 hours to 3.5 hours or by about 60%.
Cresskill is governed under the borough form of New Jersey municipal government, which is used in 218 municipalities (of the 564) statewide, making it the most common form of government in New Jersey. The governing body is comprised of the mayor and the borough council, with all positions elected at-large on a partisan basis as part of the November general election. A mayor is elected directly by the voters to a four-year term of office. The borough council includes six members elected to serve three-year terms on a staggered basis, with two seats coming up for election each year in a three-year cycle. The borough form of government used by Cresskill is a "weak mayor / strong council" government in which council members act as the legislative body with the mayor presiding at meetings and voting only in the event of a tie. The mayor can veto ordinances subject to an override by a two-thirds majority vote of the council. The mayor makes committee and liaison assignments for council members, and most appointments are made by the mayor with the advice and consent of the council. As of 2026, the mayor of the Borough of Cresskill is Republican John Morgan, who was appointed to serve a term of office ending on December 31, 2027. Members of the Cresskill Borough Council are Saverio Costa (R, 2028), Cheryl Furio (R, 2028), Arthur J. McLaughlin (D, 2026), Hector Olmo (R, 2026), Kathleen Savas (D, 2027), and Kathy M. Schultz-Rummel (R, 2027).
Sources: en.wikipedia.org
== Chemical properties == The cyclic thiourea derivative thiamazole is a white to matte brown crystalline powder with a characteristic odour. The boiling point is 280 °C (decomposition). Thiamazole is soluble in water, ethanol and chloroform, but hardly soluble in ether. Thiamazole acts as a free radical scavenger for radicals such as the hydroxyl radical (•OH) radical. It is used as free radical scavenger in organic chemistry.
The brunt of the fighting was shouldered by small, mobile rapid reaction forces, whose role was to track and eliminate the insurgents after a PLAN presence was detected. These reaction forces were attached on the battalion level and maintained at maximum readiness on individual bases. The SADF carried out mostly reconnaissance operations inside Angola, although its forces in South West Africa could fire and manoeuvre across the border in self-defence if attacked from the Angolan side. Once they reached the Cutline, a reaction force sought permission either to enter Angola or abort the pursuit. South Africa also set up a specialist unit, 32 Battalion, which concerned itself with reconnoitring infiltration routes from Angola. 32 Battalion regularly sent teams recruited from ex-FNLA militants and led by white South African personnel into an authorised zone up to fifty kilometres deep in Angola; it could also dispatch platoon-sized reaction forces of similar composition to attack vulnerable PLAN targets. As their operations had to be clandestine and covert, with no link to South African forces, 32 Battalion teams wore FAPLA or PLAN uniforms and carried Soviet weapons. Climate shaped the activities of both sides. Seasonal variations during the summer passage of the Intertropical Convergence Zone resulted in an annual period of heavy rains over northern South West Africa between February and April. The rainy season made military operations difficult.
nascent In the process of being synthesized; incomplete; not yet fully processed or mature. The term is commonly used to describe strands of DNA or RNA which are actively undergoing synthesis during replication or transcription, or sometimes a complete, fully transcribed RNA molecule before any post-transcriptional modifications have been made (e.g. polyadenylation or RNA editing), or a peptide chain actively undergoing translation by a ribosome.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.